Enfusion (NYSE:ENFN) Sets New 52-Week High Following Analyst Upgrade

Shares of Enfusion, Inc. (NYSE:ENFN) hit a new 52-week high during trading on Monday after Piper Sandler raised their price target on the stock from $10.00 to $11.50. Piper Sandler currently has a neutral rating on the stock. Enfusion traded as high as $11.50 and last traded at $11.50, with a volume of 224 shares. The stock had previously closed at $10.63.

Separately, Stifel Nicolaus raised their price target on shares of Enfusion from $11.00 to $13.00 and gave the stock a “buy” rating in a research note on Wednesday, December 18th. Three equities research analysts have rated the stock with a sell rating, one has issued a hold rating and two have given a buy rating to the stock. According to MarketBeat, Enfusion currently has a consensus rating of “Hold” and an average target price of $10.25.

Insider Buying and Selling at Enfusion

In related news, COO Neal Pawar sold 21,801 shares of the firm’s stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $10.03, for a total value of $218,664.03. Following the completion of the sale, the chief operating officer now directly owns 1,143,544 shares in the company, valued at approximately $11,469,746.32. This trade represents a 1.87 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Corporate insiders own 36.44% of the company’s stock.

Institutional Trading of Enfusion

Several institutional investors and hedge funds have recently bought and sold shares of ENFN. Centiva Capital LP increased its holdings in shares of Enfusion by 5.0% during the 3rd quarter. Centiva Capital LP now owns 25,596 shares of the company’s stock worth $243,000 after acquiring an additional 1,227 shares during the last quarter. Harbor Capital Advisors Inc. raised its position in shares of Enfusion by 12.4% in the third quarter. Harbor Capital Advisors Inc. now owns 11,887 shares of the company’s stock valued at $113,000 after purchasing an additional 1,315 shares during the period. Azora Capital LP lifted its stake in shares of Enfusion by 6.8% during the 3rd quarter. Azora Capital LP now owns 29,827 shares of the company’s stock worth $283,000 after buying an additional 1,890 shares during the last quarter. 272 Capital LP boosted its holdings in shares of Enfusion by 1.5% during the 2nd quarter. 272 Capital LP now owns 139,180 shares of the company’s stock worth $1,186,000 after buying an additional 2,000 shares during the period. Finally, The Manufacturers Life Insurance Company grew its stake in Enfusion by 27.7% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 19,562 shares of the company’s stock valued at $167,000 after buying an additional 4,239 shares during the last quarter. Institutional investors own 81.05% of the company’s stock.

Enfusion Stock Performance

The company’s fifty day simple moving average is $9.74 and its two-hundred day simple moving average is $9.02. The stock has a market capitalization of $1.35 billion, a P/E ratio of 263.07, a PEG ratio of 3.98 and a beta of 0.97.

About Enfusion

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.